Merck, Synergis & IPS Present on Engineering Document Management for Simplified Compliance & Validation
Synergis Software, a global leader in engineering document management and workflow solutions, today announced they will participate in a collaborative, live panel with leaders from Merck, known as MSD outside of the United States and Canada, and IPS-Integrated Project Services, LLC (hereinafter IPS), a recognized leader in Engineering, Procurement, Construction Management and Validation (EPCMV), to present one of the many ways MSD is leveraging the Synergis Adept platform to simplify compliance and validation across their global facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005177/en/
Engineering Document Management for Simplified Compliance & System Validation (Graphic: Business Wire)
Attendees will learn how engineering document management delivers centralized access and control of GxP documents and CAD drawings in a secure, collaborative environment to improve quality processes and simplify compliance and system validation for FDA 21-CFR Part 11 and EMA Volume 4, Annex 11.
Register now for this live 50-minute webinar, hosted by Pharmaceutical-Technology.com, taking place on Wednesday, November 9, 2022, at 8:00am ET and 2:00pm ET. You can get access to the replay here.
The three panelists include:
- Raymond Kastle, Associate Director, Supply Chain at MSD
- John Niziolek, Associate Director Computer Systems Validation and Data Integrity, IPS
- Scott Lamond, Vice President of Marketing, Synergis Software
The presentation will address the top document management concerns that life sciences organizations face in a regulated industry with a focus on MSD’s specific background, challenges, and approach.
Mr. Kastle will also share MSD’s best practices and lessons learned for implementation and user adoption. Mr. Lamond and Mr. Niziolek will share their companies’ roles in supporting MSD’s document management implementation and validation.
Key Learning Objectives:
- Lower the cost and effort of compliance and validation
- Reduce risk of noncompliance with streamlined audits
- Eliminate costly mistakes and safety issues
- Simplify collaboration and accelerate projects
“In their pursuit of simplified compliance with FDA 21-CFR Part 11 and improved data integrity, traceability, an audit trail, and record retention, MSD turned to Synergis Adept,” says Scott Lamond, vice president of marketing at Synergis Software. “Adept provides a centralized platform for document access, workflow, and control that aligns engineering, maintenance, operations, and construction teams. It empowers life sciences companies to drive standards and reduce the risk of safety and compliance issues.”
Together, Synergis and IPS bring life sciences and biotech companies the best possible solution for engineering document management software coupled with expertise and resources to ensure compliance and validation.
“IPS has developed a deep understanding of the Adept platform and the Synergis implementation process,” says John Niziolek, associate director computer systems validation and data Integrity at IPS. “Our partnership provides every client with a compliant, consistent implementation experience and ensures they benefit from industry leading technology that addresses their regulatory compliance concerns.”
Synergis Adept is used by many of the top life sciences/biotech companies, including Johnson & Johnson, Thermo Fisher Scientific, Bayer, Agilent, Astellas, bioMérieux, Elanco, and many others.
About Synergis Software
Synergis Software, a division of Synergis Technologies, LLC, is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. The Adept suite serves more than 130,000 users across dozens of industries including energy and utilities, life sciences, manufacturing, engineering and construction, and mining. Synergis' flagship product, Adept, provides fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator makes it easy to connect enterprise applications so data and business processes flow seamlessly across the entire IT infrastructure.
Synergis Software was named the customer service leader in the global engineering information management market by analyst firm Frost & Sullivan and ranks in the Top 5 globally by Helpdesk International. Adept has over 30 top placements on software review site, G2, including fastest implementation, highest user adoption, and best support. Founded in 1985, Synergis is privately owned and headquartered in Bucks County, PA.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About IPS
IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, PA-USA, IPS has over 3,000 professionals in 46 offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. For further information, please visit www.ipsdb.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005177/en/
Contact information
Scott Lamond
Vice President of Marketing
scott.lamond@synergis.com
215-302-3006
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom